Hosted on MSN9h
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What’s Next?
Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
The drug industry is having its own DeepSeek moment
It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...
No-Moat Lundbeck's Strategic Brands Drive Growth but Face Generic Pressure Amid Patent Losses
However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...
JD Supra11h
USPTO’s Proposed Terminal Disclaimer Practice
On May 10, 2024, the United States Patent and Trademark Office (“USPTO”) published a new proposed rule that would require when a patent ...
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin ...